Effects of Mediterranean Diet, Curcumin, and Resveratrol on Mild-to-Moderate Active Ulcerative Colitis: A Multicenter Randomized Clinical Trial

Author:

Erol Doğan Özge12ORCID,Karaca Çelik Kezban Esen3,Baş Murat3ORCID,Alan Eyüp Hakan4,Çağın Yasir Furkan5ORCID

Affiliation:

1. Department of Nutrition and Dietetics, Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, Turkey

2. Department of Health Care Services, Vocational School of Health Services, Ardahan University, Ardahan 75002, Turkey

3. Department of Nutrition and Dietetics, Faculty of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, Turkey

4. Department of Gastroenterology, Malatya Training and Research Hospital, Malatya 44330, Turkey

5. Department of Gastroenterology, Faculty of Medicine, İnönü University, Malatya 44280, Turkey

Abstract

This study aimed to investigate the effects of the Mediterranean diet (MD), combined with curcumin and resveratrol supplementation, on disease activity, serum inflammatory markers, and quality of life in patients with mild-to-moderate active ulcerative colitis (UC). This study was designed as a prospective multicenter three-arm randomized controlled trial. Participants were randomized to the MD, MD + curcumin, and MD + resveratrol groups. All participants were placed on the MD for 8 weeks. The MD + curcumin group also received 1600 mg/day of curcumin supplementation, whereas the MD + resveratrol group received 500 mg/day of resveratrol supplementation for 8 weeks. Anthropometric measurements, Truelove–Witts Index, Short Form-36, Inflammatory Bowel Disease Questionnaire, Mediterranean Diet Adherence Scale (MEDAS), and laboratory tests were performed at baseline and postintervention. Within-group comparisons showed that MD, MD + curcumin, and MD + resveratrol interventions were effective in reducing disease activity and inflammation and improving quality of life in individuals with UC (p < 0.05). Between-group comparisons revealed no significant difference in all parameters except for the pain subparameter of SF-36 and the MEDAS score (p < 0.05). The MD is an effective and safe intervention to be used in clinical practice in individuals with UC.

Publisher

MDPI AG

Reference71 articles.

1. Ulcerative colitis—Diagnostic and therapeutic algorithms;Kucharzik;Dtsch. Ärzteblatt Int.,2020

2. Patient considerations in the management of ulcerative colitis–role of vedolizumab;Kothari;Ther. Clin. Risk Manag.,2015

3. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review;Molodecky;Gastroenterology,2012

4. World gastroenterology organisation global guidelines inflammatory bowel disease: Update August 2015;Bernstein;J. Clin. Gastroenterol.,2016

5. Significant Racial and Ethnic Disparities Exist in Health Care Utilization in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis;Tandon;Inflamm. Bowel Dis.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3